Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy

Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/3/e003408corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
by: Yang Zhao, et al.
Published: (2022-03-01)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
by: Mitsuo Oshimura, et al.
Published: (2020-10-01)

Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation
by: Chengyu Shi, et al.
Published: (2024-12-01)

Ultrasound-activated miR-195-5p/shikonin nanobubbles remodel immunosuppressive microenvironment via immunogenic cell death to potentiate PD-1/PD-L1 blockade in hepatocellular carcinoma
by: Yandi Tan, et al.
Published: (2025-10-01)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
by: Min Li, et al.
Published: (2021-10-01)

PD-L1+ macrophages suppress T cell-mediated anticancer immunity
by: Peng Liu, et al.
Published: (2024-12-01)

Utilization of exosome-based therapies to augment anti-PD-1/PD-L1 therapies
by: John S. Wang, et al.
Published: (2025-04-01)

Macroscopic bubble generation promoted by nanobubble seeds as a traceless anti-fluctuation strategy for water splitting
by: Sheng Yang, et al.
Published: (2025-07-01)

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
by: Peng Gao, et al.
Published: (2025-08-01)

Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment
by: Lin Yao, et al.
Published: (2025-04-01)

Faecalibacterium prausnitzii promotes anti-PD-L1 efficacy in natural killer/T-cell lymphoma by enhancing antitumor immunity
by: Zhuangzhuang Shi, et al.
Published: (2025-07-01)

Microfluidic nanobubbles produced using a micromixer for ultrasound imaging and gene delivery
by: Taiki Yamaguchi, et al.
Published: (2025-04-01)

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
by: Jinghan Li, et al.
Published: (2024-02-01)

Correction: Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint Inhibition to boost anticancer immunity
by: Yanhong Liu, et al.
Published: (2025-06-01)

Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer
by: Chengquan Shen, et al.
Published: (2025-07-01)

Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy
by: Jing Cao, et al.
Published: (2025-04-01)

Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation
by: Chengyu Shi, et al.
Published: (2022-11-01)

Nanobubbles based on repeated compression for contrast-enhanced ultrasound (CEUS) imaging of renal fibrosis
by: Zhang Chenyi, et al.
Published: (2025-01-01)

TRPC6-targeted dexamethasone nanobubbles with ultrasound-guided theranostics for adriamycin-induced nephropathy
by: Lin Wu, et al.
Published: (2025-05-01)

Phosphorodiamidate Morpholino Oligomers-Loaded Nanobubbles for Ultrasound-Mediated Delivery to the Myocardium in Muscular Dystrophy
by: Yoko Endo-Takahashi, et al.
Published: (2025-02-01)

Ultrasound-driven ROS-scavenging nanobubbles for synergistic NASH treatment via FXR activation
by: Jianru Lin, et al.
Published: (2025-07-01)

WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis
by: Weiliang Jiang, et al.
Published: (2025-02-01)

Advances of therapeutic microbubbles and nanobubbles
by: Huang Bin, et al.
Published: (2023-08-01)

Combination of low-intensity pulsed ultrasound irradiating immune organs with immune checkpoint blockade augments systemic anti-tumor immunity on low tumor burden 4T-1 breast cancer
by: Jixi Li, et al.
Published: (2025-08-01)

MRI radiomics model for predicting tumor immune microenvironment types and efficacy of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma
by: Rui Zhang, et al.
Published: (2025-07-01)

Ultrasound-responsive nanobubble-mediated sonodynamic therapy sensitizes disulfidptosis in the treatment of liver hepatocellular carcinoma
by: Yichi Chen, et al.
Published: (2025-07-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients
by: Luisa Amato, et al.
Published: (2025-04-01)

PAR2 deficiency impairs antitumor immunity and attenuates anti-PD1 efficacy in colorectal cancer
by: Zilin Liu, et al.
Published: (2025-05-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Taurine-mediated metabolic immune crosstalk indicates and promotes immunosuppression with anti-PD-1 resistance in bladder cancer
by: Zhengfang Liang, et al.
Published: (2025-06-01)

The efficacy and immune-mediated safety of PD-1/PD-L1 combined with neoadjuvant chemotherapy in triple-negative breast cancer: a meta-analysis
by: Xiao Yan, et al.
Published: (2025-08-01)

Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
by: Shuling Shi, et al.
Published: (2024-07-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

Correction: Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer
by: Minmin Lan, et al.
Published: (2025-02-01)

Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer
by: Yang Tan, et al.
Published: (2025-04-01)

Low‐Intensity Focused Ultrasound‐Responsive Nanobubbles Enhance Thrombus Targeting and Penetration for Highly Effective Thrombolytic Therapy
by: Wenli Zhang, et al.
Published: (2025-06-01)

Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity
by: Yanhong Liu, et al.
Published: (2025-03-01)

TRIM21-mediated METTL3 degradation promotes PDAC ferroptosis and enhances the efficacy of Anti-PD-1 immunotherapy
by: Wenhao Mao, et al.
Published: (2025-04-01)

FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma
by: Fengyu Zhao, et al.
Published: (2025-05-01)